Drug Profile
Research programme: VEGF receptor 2 antagonists - Astellas Pharma
Alternative Names: Flk-1/KDR inhibitors - Astellas Pharma; YM-231146; YM-359445Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Japan (PO)
- 29 Sep 2006 Data presented at the 232nd American Chemical Society National Meeting (232nd-ACS-2006) have been added to the pharmacokinetics and the Cancer pharmacodynamics section
- 17 Jul 2006 A preclinical study has been added to the pharmacokinetics and Cancer pharmacodynamics sections